Recombinant FNDC4 Protein, Human (ECD, Fc Tag) Recombinant Proteins The human FNDC4 (NP_073734.1) (Met1-Thr167) was expressed with the Fc region of mouse IgG1 at the C-terminus The recombinant human FNDC4 consists 357a.a and predicts a molecular weight of 39.7 kDa.
$ $99 In stock
Formulation: The recombinant human FNDC4 consists 357a.a and predicts a molecular weight of 39.7 kDa.
Source: HEK293 Cells
Usage: Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use

Recombinant FNDC4 Protein, Human (ECD, Fc Tag)

Formulation: Recombinant FNDC4 Protein was lyophilized from sterile PBS, pH 7.4.1

Source: HEK293 Cells

Product Name Recombinant FNDC4 Protein, Human (ECD, Fc Tag)
Product Type Recombinant Protein
Source HEK293 Cells
Formulation Recombinant FNDC4 Protein was lyophilized from sterile PBS, pH 7.4.1
Molecular Weight The recombinant human FNDC4 consists 357a.a and predicts a molecular weight of 39.7 kDa.
Endotoxin < 1.0 EU per μg protein as determined by the LAL method
Purity Greater than 85.4% as determined by SDS-PAGE.
Description The human FNDC4 (NP_073734.1) (Met1-Thr167) was expressed with the Fc region of mouse IgG1 at the C-terminus
Host Species Homo sapiens (Human)
Usage Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Storage Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
AA Sequence Met1-Thr167
Product Background FNDC4 acts as an anti-inflammatory factor on macrophages and improves mouse model of induced colitis. FNDC4 could suppress osteoclast formation via NF-kappaB pathway and downregulation of CXCL1. Analysis of binding of FNDC4 to different immune cell types reveals strong and specific binding to macrophages and monocytes. FNDC4 treatment of bone marrow-derived macrophages in vitro results in reduced phagocytosis, increased cell survival and reduced proinflammatory chemokine expression. Hence, treatment with FNDC4 results in a state of dampened macrophage activity, while enhancing their survival. That FNDC4 may be a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases.
Memo FRCP1 Protein, Human
Terminal Asp 45
Bioactivity Please contact us for detailed information